

APOSTEL-AS Protocol

1 Full title:

2 Development of the Advised Protocol for OCT Study Terminology and Elements Anterior
3 Segment OCT extension reporting guidelines (APOSTEL-AS): Study protocol

4

5 Short title

6 APOSTEL-AS extension

7

8 Authors: Ameenat L Solebo PhD^{1,2}, Marcus Ang PhD^{3,4}, Alice Bellchambers MBBS^{1,5}, Colin
9 J Chu PhD^{6,7}, Prof Alastair K Denniston FRCOphth^{8,9}, Prof Laura E Downie PhD¹⁰, Thomas
10 Evans¹¹, Alexander S Fraser MD¹², Scott Hau MCOptom⁶, Prof Alex S Huang MD¹³, Prof
11 Pearse A. Keane FRCOphth^{6,7}, Xiaoxuan Liu PhD^{8,9,14}, Prof Jodhbir S Mehta PhD^{3,15},
12 Giovanni Ometto PhD^{5,6,16}, Prof Axel Petzold MD PhD^{6,17,18}, Edmund Tsui MD¹⁹, Tamara S
13 Fraser MD²⁰, Prof Benjamin Xu PhD²¹

14

- 15 1. Population, Policy and Practice Department, UCL GOS Institute of Child Health,
16 London, UK; Great Ormond Street Hospital, London, UK,
- 17 2. Great Ormond Street NIHR Biomedical Research Centre, London, UK
- 18 3. Cornea and External Eye Disease Service and Refractive Service, Singapore National
19 Eye Center, Singapore
- 20 4. DUKE-NUS Department of Ophthalmology and Visual Sciences, Singapore
- 21 5. University Hospitals Sussex NHS Foundation Trust, UK
- 22 6. Moorfields NIHR Biomedical Research Centre, London, UK
- 23 7. UCL Institute of Ophthalmology, London, UK
- 24 8. NIHR Birmingham Biomedical Research Centre, Birmingham, UK
- 25 9. College of Medicine and Health, University of Birmingham, Birmingham, UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

APOSTEL-AS Protocol

- 26 10. Department of Optometry and Vision Sciences, The University of Melbourne,
27 Parkville, Victoria, Australia
- 28 11. Department of Ophthalmology, Sheffield Teaching Hospitals NHS Foundation Trust,
29 Sheffield, UK
- 30 12. Trinidad Eye Hospital, San Fernando, Trinidad and Tobago
- 31 13. Hamilton Glaucoma Center, The Viterbi Family Department of Ophthalmology,
32 Shiley Eye Institute, University of California, San Diego, CA, USA
- 33 14. Birmingham Health Partners Centre for Regulatory Science and Innovation
- 34 15. Singapore Eye Research Institute, Singapore.
- 35 16. City St George's, University of London, Department of Optometry & Visual
36 Sciences, London, UK.
- 37 17. University College London, UCL Institute of Neurology, London UK
- 38 18. Departments of Ophthalmology and Neurology, Amsterdam UMC, NL.
- 39 19. Ocular Inflammatory Disease Center, UCLA Stein Eye Institute, David Geffen School
40 of Medicine at UCLA, Los Angeles, California, USA
- 41 20. Mid South Essex NHS Foundation Trust, Essex, UK
- 42 21. USC Roski Eye Institute, Keck School of Medicine at USC, Los Angeles, California,
43 USA

44

45 Corresponding author: Ameenat Lola Solebo, UCL GOS Institute of Child Health, 30

46 Guilford Street, London, WC1N 1EH, UK. Email a.solebo@ucl.ac.uk

47

48

APOSTEL-AS Protocol

49 **Abstract**

50 Background:

51 Anterior segment optical coherence tomography (AS-OCT) is emerging as a valuable
52 diagnostic, monitoring and predictive tool. Clinical utility has been suggested for ophthalmic
53 disorders such as glaucoma, corneal disease, cataract and uveitis, which taken together
54 comprise the majority of the blinding conditions affecting working age individuals globally.
55 The current absence of guidelines for reporting OCT studies that quantitatively assess the
56 anterior segment is an obstacle to reproducibility and interoperability. To provide this
57 guidance, we aim to extend the existing Advised Protocol for OCT Study Terminology and
58 Elements (APOSTEL) guidelines, to ensure applicability to AS-OCT.

59 Methods

60 In line with EQUATOR Network guidance for the development of reporting guidelines,
61 APOSTEL-AS will be developed through a staged consensus process involving literature
62 review and Delphi consensus across an international multi-disciplinary stakeholder group,
63 overseen by a multi-disciplinary multi-national Steering Committee. The systematic scoping
64 review will be used to generate candidate items, support the development of a consensus
65 nomenclature for AS-OCT representation of ocular structure, and to form Delphi group
66 membership. Delphi methodology, used to consider items for inclusion, rewording or
67 exclusion, will be undertaken in line with ACCORD (ACcurate COnsensus Reporting
68 Document) guidance, with at least two rounds of Delphi survey, inclusion consensus
69 threshold set at 80%, and steering committee reviews between rounds. The resultant
70 APOSTEL-AS guideline will undergo piloting before dissemination of the final version.

71 Discussion

72 The APOSTEL-AS checklist, with minimum and recommended items to be reported about
73 study methods, should provide timely support for researchers to ensure future standardisation,

APOSTEL-AS Protocol

- 74 interoperability and reproducibility of reported work, hastening implementation and the
- 75 translation of knowledge into clinically beneficial action.

76 **Summary**

77 Anterior segment optical coherence tomography (AS-OCT) is emerging as a valuable
78 diagnostic, monitoring and predictive tool. To address the current absence of guidelines for
79 reporting OCT studies which quantitatively assess the anterior segment, we aim to extend the
80 existing Advised Protocol for OCT Study Terminology and Elements (APOSTEL)
81 recommendations, to enable applicability to studies involving AS-OCT. Following steering
82 committee formation, literature review will be used to generate items additional to those
83 within the current APOSTEL guidance, to create a consensus nomenclature and the Delphi
84 membership. A multi-round Delphi exercise, with the inclusion consensus threshold set at
85 80%, will be used to generate reporting guidance items, with process overview by the
86 steering committee. The resultant guideline will be piloted prior to dissemination, providing a
87 timely support tool for researchers to ensure future standardisation, interoperability and
88 reproducibility of reported work, hastening the implementation and the translation of
89 knowledge on the utility of AS-OCT into clinical benefit.

90

91 **Introduction**

92 Optical coherence tomography (OCT) has changed the face of ophthalmic clinical practice
93 and medical research. The research and clinical utility of ocular OCT biomarkers has been
94 demonstrated within ophthalmology,(1–3) and beyond the eye.(4) Quantitative data from
95 posterior segment ocular OCT, such as retinal nerve fibre layer or central macular thickness,
96 have been used as diagnostic, predictive, prognostic and monitoring biomarkers for
97 inflammatory, degenerative, vascular, and metabolic disorders.(4–7)

98

99 The validation and adoption of these biomarkers has been enabled by the standardisation and
100 harmonisation of the reporting of research findings within the underpinning evidence base.

101 The 2016 and 2021 Advised Protocol for OCT Study Terminology and Elements

102 (APOSTEL) and APOSTEL2.0 recommendations(8,9) for reporting quantitative retinal OCT

103 studies strengthened reproducibility and interoperability across OCT studies of the posterior

104 segment of the eye. However, some aspects of the current APOSTEL guidance are not

105 applicable to anterior segment OCT (AS-OCT) studies. AS-OCT is being used to derive

106 quantitative data from images of the normal physiology of the anterior ocular structure, data

107 which carry clinical utility for the diagnosis and management of diseases involving those

108 structures. These diseases include tear film disorders, corneal pathology, glaucoma, cataract

109 and anterior uveitis,(10–16) disorders which, collectively, constitute the most common causes

110 of working aged blindness globally.(17)

111

112 In order to improve the reproducibility and interoperability of AS-OCT studies, we aim to

113 develop a checklist of the core information that should be provided when reporting studies in

114 which the quantitatively assessment of AS OCT structures is undertaken. This checklist will

115 be developed using the framework of the current APOSTEL recommendations.(8)

APOSTEL-AS Protocol

116

117 **Materials and methods**

118 APOSTEL-AS has been registered as a reporting guideline under development on the
119 EQUATOR (Enhancing the QUality and Transparency Of health Research) library of
120 reporting guidelines and will be developed in accordance with the EQUATOR Network's
121 methodological framework. A steering committee with representation of expertise in tear
122 film, corneal, lens, glaucoma and uveitic disorders, expertise in multinational, multi-
123 disciplinary consensus exercises, and including investigators involved in developing the
124 APOSTEL guidelines has been formed to oversee the conduct and methodology of the study.
125 A multi-stage Delphi consensus approach will be used (figure 1).

126

127 **Figure 1. APOSTEL-AS development process**

128 **Further Delphi rounds may be needed to reach consensus*

129

130 Literature review and candidate item generation

131 An initial list of candidate items for the APOSTEL-AS checklist will be generated through
132 review of the published literature and consultation with the steering committee (SC). A
133 database search will be performed using the terms "anterior segment optical coherence
134 tomography" (see supplemental document, search approach) to identify eligible studies.
135 Eligibility criteria comprise publications reporting the analysis of quantitative data derived
136 from AS-OCT acquired from human eyes of living participants. Specific considerations for
137 Screening, selection AS-OCT will be identified from these studies and extracted as potential
138 reporting items using a specific data collection form *developed de novo* by the SC. and data
139 extraction to the data collection form (DCF) will be undertaken independently by at least two
140 investigators. Items will be reframed as candidate reporting items ahead of the consensus

APOSTEL-AS Protocol

141 process. The SC will also create a consensus nomenclature for ocular anterior segment
142 structures visible on axial cross sectional OCT imaging. This consensus nomenclature will be
143 developed by the APOSTEL-AS SC using the nominal group technique, with consensus
144 reached through discussion and majority voting.

145

146 Delphi consensus group membership:

147 Membership of the Delphi consensus group will be informed by the findings of the
148 systematic review. Corresponding authors of studies reporting quantitative anterior segment
149 OCT results will be contacted by email, requesting a response within six weeks. Reminder
150 emails will be sent three weeks later. Records will be kept of attempted email and confirmed
151 contact. Response rates will be reported using those who complete the Delphi as the
152 nominator, and those for whom receipt of the email can be confirmed as the denominator.

153 Other stakeholders to be identified and invited by the SC to join the Delphi consensus group
154 comprise eye healthcare professionals, patients, methodologists, statisticians, computer
155 scientists, industry representatives, health informaticists, and journal editors. Experts will be
156 allowed to support snowball recruitment (i.e., to suggest additional experts). Records will be
157 kept of all those successfully contacted, either directly by the SC or as corresponding authors,
158 or indirectly through snowball recruitment.

159

160 Online Questionnaire 1 (Delphi 1):

161 Participants will be given written information about the study and asked to state their
162 professional role, region of origin, and level of expertise (using years active). The candidate
163 reporting items generated by the systematic review will be presented to the Delphi consensus
164 group members, alongside the existing APOSTEL 2.0 items. Members will be asked to vote
165 on each item using a 3-point scale: not important, important but not critical, and important

APOSTEL-AS Protocol

166 and critical. They will also be asked about their agreement on the wording of each item and
167 given the opportunity to submit free text comments about suggested amendments to wording
168 of additional items, and invited to suggest additional items.

169

170 OQ2 (Expert Group virtual meeting):

171 We will then form a panel of experts comprising the SC and selected members of the Delphi
172 consensus group (ensuring representation of stakeholder groups), who will convene at a
173 virtual meeting. The aggregated results of the initial questionnaire, comments made by
174 participants) will be reviewed by the panel. Following open discussion of the Delphi results,
175 anonymous electronic voting will be used to include or exclude each reworded, amended, or
176 newly suggested item. An 80% threshold will be used to demonstrate majority consensus for
177 the inclusion of an item.

178

179 OQ3 (Delphi 2): The included items will be considered in a second Delphi round by the

180 original Delphi consensus group. In this round, participants will be asked to approve or reject
181 the list of APOSTEL-AS items. Items achieving consensus $\geq 80\%$ will be included. Any item
182 which does not achieve consensus but is approved by the majority (51-79% inclusive) will be
183 reconsidered by the expert group for consideration following further amendment or
184 refinement, and representation in a subsequent round (Delphi 3).

185

186 OQ4 (Delphi 3): Those items that reached majority consensus but did not achieve the 80%

187 consensus threshold will be represented to the Delphi consensus group following amendment
188 by the SC for one final Delphi round. Participants will again be asked to approve or reject the
189 items. Again, items achieving consensus $\geq 80\%$ will be included. Any item that does not
190 achieve consensus but is approved by the majority (51-79% inclusive) will be reconsidered

APOSTEL-AS Protocol

191 within subsequent Delphi rounds (OQ5+) by the expert group for consideration for further
192 amendment or refinement prior to inclusion in the penultimate list.

193

194 Guideline pilot

195 The penultimate guideline will be checked by the Operations team (ALS, SD, AB, AF, TT) to
196 ensure its clarity. It will then be presented to at least five stakeholders for piloting. The
197 stakeholders participating in this pilot will comprise Delphi consensus participants who were
198 not part of the expert group, or additional external experts identified following the start of the
199 Delphi process. The Operations team will use feedback from this pilot to refine the guideline
200 and produce the final version of the checklist.

201

202 Ethics approval for this work has been granted by the University College London
203 Institutional Review Board (UCL Research Ethics Committee Approval ID Number:
204 26253/001). Informed electronic consent will be obtained from consensus group members.

205

206 **Discussion**

207 The APOSTEL-AS recommendations will be an extension to the current APOSTEL
208 guidelines, adding specific parameters for the reporting of AS-OCT data. AS-OCT is
209 increasingly being used to derive quantitative data from images of normal physiology and for
210 diseases involving the anterior segment of the eye. There are several differences in the
211 acquisition and analysis of anterior versus posterior segment OCT images. Whilst posterior
212 segment OCT (PS-OCT) concerns images of tissues with similar refractive indices and
213 typically measuring no more than 1mm in depth (as measured from the inner limiting
214 membrane to the sclera), with the '*en face*' area of interest typically being 4mm², the ocular

APOSTEL-AS Protocol

215 structures imaged in AS-OCT are arranged over a greater depth (at least 10mm, as measured
216 from the corneal epithelium to the anterior hyaloid area) and with a much wider area of
217 interest depending on the clinical or research need.(18) Furthermore, whilst the posterior
218 segment tissues minimally scatter light, there are unique features related to light
219 transmissibility of the different anterior ocular structures, from the optically clear cornea to
220 the optically opaque sclera.(18) These considerations differentiate AS-OCT from PS-OCT,
221 but it is also likely that these challenges result in heterogeneity of study methods, including
222 acquisition processes, image quality assessment, data extraction and image analysis across
223 the AS-OCT literature. APOSTEL-AS will provide timely support for users of AS-OCT, to
224 ensure future standardisation, interoperability and reproducibility of reported research and
225 clinical findings.

226

227 A limitation of the approach described in this protocol is the restriction of the identification
228 of potential consensus group members to those researchers who have published eligible
229 studies within the preceding four years. High impact, novel, innovative imaging studies may
230 require lengthy recruitment periods, which may mean that our time-restricted approach does
231 not involve scientists whose work is not yet disseminated through peer-reviewed
232 publications. The use of ‘snowball’ extension (i.e. consensus group members identifying
233 other potential members) should help to address this limitation. Strengths of the approach
234 include the involvement of a wide range of stakeholder expertise and experience, across
235 multiple countries, with collection of information about their degree of experience and
236 expertise to inform the contextualisation of responses. Development of items will be
237 underpinned by a comprehensive systematic review, with collection of data from manuscripts
238 published over the last 20 years. It is acknowledged that this comprehensiveness may result

APOSTEL-AS Protocol

239 in the collection of historical data from imaging platforms that are no longer in use, due to
240 being superseded by more contemporary devices.

241

242 Several consensus methods exist for the capture and description of consensus across multi-
243 disciplinary groups. The nominal group technique (NGT) was selected for the initial activities
244 of the SC, in view of its structured sequence of events, principal of equal participation, and
245 promotion of diversity in opinion, which should support the work of this smaller group.(19)
246 NGT consensus exercises can be time consuming, particularly for large groups, but this
247 process will benefit from facilitation undertaken by subject matter experts with experience in
248 supporting consensus initiatives.(20,21) The selection of the Delphi method for the
249 development of the checklist enables this activity to be undertaken by a large, geographically
250 and scientifically diverse group with different degrees and spheres of experience and
251 expertise. A recently published EQUATOR (Enhancing the QUality and Transparency Of
252 health Research) guideline for reporting consensus-based methods in biomedical research and
253 clinical practice (the ACCurate COnsensus Reporting Document, or ACCORD) will be used
254 to report the study findings.(19)

255

256 The original APOSTEL checklist was developed following concerns around the absence of
257 consensus around quality control criteria for posterior segment OCT imaging.(9) Similar
258 concerns are emerging for AS-OCT imaging, with recognition of this issue being a particular
259 obstacle to the potentially transformative role of artificial intelligence (AI) approaches to
260 image analysis and the development of imaging-based biomarkers.(22,23) AI approaches
261 hold the promise of dramatically increasing the utility of clinical images, with deep learning
262 (DL) based image analysis in particular proving non-inferior to expert human
263 assessment.(12,24,25) Human analysis of the quantitative information that can be extracted

APOSTEL-AS Protocol

264 from anterior segment structures is subjective, open to inter- and intraobserver variability,
265 and time consuming.(26) DL image analysis methods would provide objective, repeatable,
266 reliable OCT biomarkers, but these approaches require large (or harmonised), diverse,
267 annotated datasets. The current absence of explicit and comprehensive reporting of AS-OCT
268 study methods is an obstacle to comparison or collation of existing annotated imaging
269 datasets. Through the wide dissemination and uptake of the APOTEL-AS guidance, enabled
270 by ensuring accessibility in open access formats and translation into other languages as
271 directed and supported by stakeholders, this obstacle should be addressed.

272

273 **Authors' contributions**

274 Conceptualisation and manuscript drafting: AL Solebo

275 All authors contributed to study design, manuscript editing and final approval for submission.

276

277 **Acknowledgments**

278 We thank the Enhancing the Quality and Transparency of health research Network

279 (EQUATOR Network) team for their support with study development. This work was

280 supported by an NIHR Clinician Scientist award (CS-2018-18-ST2-005) and Fight for Sight

281 (SGAGUK2207).

282

283 **References**

- 284 1. Hui VWK, Szeto SKH, Tang F, Yang D, Chen H, Lai TYY, et al. Optical Coherence
285 Tomography Classification Systems for Diabetic Macular Edema and Their
286 Associations With Visual Outcome and Treatment Responses - An Updated Review.
287 Asia Pac J Ophthalmol (Phila). 2022 Jun 1;11(3):247–57.

APOSTEL-AS Protocol

- 288 2. Hood DC, La Bruna S, Tsamis E, Thakoor KA, Rai A, Leshno A, et al. Detecting
289 glaucoma with only OCT: Implications for the clinic, research, screening, and AI
290 development. *Prog Retin Eye Res.* 2022 Sep;90:101052.
- 291 3. Virgili G, Menchini F, Casazza G, Hogg R, Das RR, Wang X, et al. Optical coherence
292 tomography (OCT) for detection of macular oedema in patients with diabetic
293 retinopathy. *Cochrane Database Syst Rev.* 2015 Jan 7;1:CD008081.
- 294 4. Wagner SK, Fu DJ, Faes L, Liu X, Huemer J, Khalid H, et al. Insights into Systemic
295 Disease through Retinal Imaging-Based Oculomics. *Transl Vis Sci Technol.* 2020 Feb
296 12;9(2):6.
- 297 5. Bostan M, Li C, Sim YC, Bujor I, Wong D, Tan B, et al. Combining retinal structural
298 and vascular measurements improves discriminative power for multiple sclerosis
299 patients. *Ann N Y Acad Sci.* 2023 Sep 1;
- 300 6. Chen S, Zhang D, Zheng H, Cao T, Xia K, Su M, et al. The association between retina
301 thinning and hippocampal atrophy in Alzheimer's disease and mild cognitive
302 impairment: a meta-analysis and systematic review. *Front Aging Neurosci.*
303 2023;15:1232941.
- 304 7. Wagner SK, Romero-Bascones D, Cortina-Borja M, Williamson DJ, Struyven RR,
305 Zhou Y, et al. Retinal Optical Coherence Tomography Features Associated With
306 Incident and Prevalent Parkinson Disease. *Neurology.* 2023 Aug 21;
- 307 8. Aytulun A, Cruz-Herranz A, Aktas O, Balcer LJ, Balk L, Barboni P, et al. APOSTEL
308 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography
309 Studies. *Neurology.* 2021 Jul 13;97(2):68–79.
- 310 9. Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH,
311 Lagreze WA, et al. The APOSTEL recommendations for reporting quantitative optical
312 coherence tomography studies. *Neurology.* 2016 Jun 14;86(24):2303–9.

APOSTEL-AS Protocol

- 313 10. Chen C, Lee Y, Gerber MJ, Cheng H, Yang Y, Govetto A, et al. Intraocular robotic
314 interventional surgical system (IRISS): Semi-automated OCT-guided cataract removal.
315 The International Journal of Medical Robotics and Computer Assisted Surgery. 2018
316 Dec 28;14(6).
- 317 11. Sharma R, Sharma A, Arora T, Sharma S, Sobti A, Jha B, et al. Application of anterior
318 segment optical coherence tomography in glaucoma. *Surv Ophthalmol*. 2014
319 May;59(3):311–27.
- 320 12. Santos VA dos, Schmetterer L, Stegmann H, Pfister M, Messner A, Schmidinger G, et
321 al. CorneaNet: fast segmentation of cornea OCT scans of healthy and keratoconic eyes
322 using deep learning. *Biomed Opt Express*. 2019 Feb 1;10(2):622.
- 323 13. Etherton K, Rahi JS, Petrushkin H, Dick AD, Akbarali S, Pattani R, et al. Quantitative
324 and qualitative assessment of anterior segment optical coherence tomography capture
325 of disease state in childhood anterior uveitis. *Br J Ophthalmol*. 2023 Jul;107(7):966–
326 72.
- 327 14. Tsui E, Chen JL, Jackson NJ, Leyva O, Rasheed H, Baghdasaryan E, et al.
328 Quantification of Anterior Chamber Cells in Children With Uveitis Using Anterior
329 Segment Optical Coherence Tomography. *Am J Ophthalmol*. 2022 Sep;241:254–61.
- 330 15. Bao YK, Xu BY, Friedman DS, Cho A, Foster PJ, Jiang Y, et al. Biometric Risk
331 Factors for Angle Closure Progression After Laser Peripheral Iridotomy. *JAMA*
332 *Ophthalmol*. 2023 Jun 1;141(6):516–24.
- 333 16. Xu BY, Friedman DS, Foster PJ, Jiang Y, Porporato N, Pardeshi AA, et al. Ocular
334 Biometric Risk Factors for Progression of Primary Angle Closure Disease: The
335 Zhongshan Angle Closure Prevention Trial. *Ophthalmology*. 2022 Mar;129(3):267–75.

APOSTEL-AS Protocol

- 336 17. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli M V, et
337 al. Global causes of blindness and distance vision impairment 1990–2020: a systematic
338 review and meta-analysis. *Lancet Glob Health*. 2017 Dec;5(12):e1221–34.
- 339 18. Xie X, Corradetti G, Song A, Pardeshi A, Sultan W, Lee JY, et al. Age- and refraction-
340 related changes in anterior segment anatomical structures measured by swept-source
341 anterior segment OCT. *PLoS One*. 2020 Oct 23;15(10):e0240110.
- 342 19. Gattrell WT, Hungin AP, Price A, Winchester CC, Tovey D, Hughes EL, et al.
343 ACCORD guideline for reporting consensus-based methods in biomedical research
344 and clinical practice: a study protocol. *Res Integr Peer Rev*. 2022 Dec 7;7(1):3.
- 345 20. Solebo AL, Rahi JS, Dick AD, Ramanan A V, Ashworth J, Edelsten C. Areas of
346 agreement in the management of childhood non-infectious chronic anterior uveitis in
347 the UK. *British Journal of Ophthalmology*. 2020 Jan;104(1):11–6.
- 348 21. Solebo AL, Kellett S, Rahi J, Pattani R, Edelsten C, Dick AD, et al. Development of a
349 Nationally Agreed Core Clinical Dataset for Childhood Onset Uveitis. *Front Pediatr*.
350 2022 Jun 21;10.
- 351 22. Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, et al. The OSCAR-IB
352 Consensus Criteria for Retinal OCT Quality Assessment. *PLoS One*. 2012 Apr
353 19;7(4):e34823.
- 354 23. Petzold A, Albrecht P, Balcer L, Bekkers E, Brandt AU, Calabresi PA, et al. Artificial
355 intelligence extension of the OSCAR-IB criteria. *Ann Clin Transl Neurol*. 2021 Jul
356 19;8(7):1528–42.
- 357 24. Bolo K, Apolo Aroca G, Pardeshi AA, Chiang M, Burkemper B, Xie X, et al.
358 Automated expert-level scleral spur detection and quantitative biometric analysis on
359 the ANTERION anterior segment OCT system. *Br J Ophthalmol*. 2024 May
360 21;108(5):702–9.

APOSTEL-AS Protocol

- 361 25. Xu BY, Chiang M, Pardeshi AA, Moghimi S, Varma R. Deep Neural Network for
362 Scleral Spur Detection in Anterior Segment OCT Images: The Chinese American Eye
363 Study. *Transl Vis Sci Technol.* 2020 Mar;9(2):18.
- 364 26. Akbarali S, Rahi JS, Dick AD, Parkash K, Etherton K, Edelsten C, et al. Imaging-
365 Based Uveitis Surveillance in Juvenile Idiopathic Arthritis: Feasibility, Acceptability,
366 and Diagnostic Performance. *Arthritis Rheumatol.* 2021 Feb;73(2):330–5.
- 367
- 368

APOSTEL-AS Protocol

369 **Supporting documents**

370 Supplemental document 1: Literature search strategy